Small Company Champion & Lemming Investors Research and Newsletter Updates

Thursday, 15 April 2021

Open Orphan - Potential demerger of certain non-core assets


 

Shares Open Orphan Plc (AIM: ORPH), took a tumble in early trading (recovering almost all the lost ground at the end of trading) likely due to some confusion over the T&Cs of being handed what is essentially free money. The specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces that it is at an advanced stage in planning for a possible spin-out of certain non-core Development IP Assets. However, the use of the word lock-in appears to have spooked some of the lemming natives amongst us. 







Sunday, 11 April 2021

Open Orphan - Launch of Disease in Motion platform Launch

 



 

Open Orphan Plc (ORPH), a rapidly growing speciality pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan, has officially launched its Disease in Motion® platform. This unique data-focused platform includes clinical, immunological, virological and digital (wearable) biomarkers. The Disease in Motion platform has multiple infectious disease applications that apply to a wide variety of end-users, including big tech, wearables, pharma and biotech companies.

 



POPULAR COMPANIES